Market Access

ClearNetwork will be available for a plan sponsor’s list of covered generic, branded, and specialty drugs across 65,000 retail pharmacies in the Express Scripts network.

Blue Fin Group exec speaks on his upcoming feature.

SVP and Managing Director for Blue Fin Group offers a synopsis of the conference opener.

Director of Berkeley Research Group explains changes to 340B moving forward.

Berkeley Research Group executive speaks about the role of manufacturers in 340B pricing.

Berkeley Research Group Director discusses what to expect at his upcoming session.

Tirzepatide (Zepbound; Eli Lilly and Company) will hit the US market by the end of 2023 with a list price of $1,059.87.

Study describes how biotech startups can avoid competing with large pharma companies for financing.

HDA research reveals that 95% of pharma transactions move through the traditional distribution channel.

Payers won’t let these products break the bank.

The conference will focus on the full breadth of commercialization strategies and operations.

Boehringer Ingelheim’s unbranded adalimumab-adbm biosimilar will be available at an 81% discount to adalimumab (Humira).

The debate continues as to how government payers should weigh covering healthcare needs versus other budget items.

These programs can negatively impact patients trying to reach their deductible.

The trend is continuing for brands and even for some specialty products.

An analysis by 3 Axis Advisors has found that there is a large variability in pharmacy reimbursement of prescription drugs depending on PBM contracts with insurers. This creates a system with huge inconsistencies on the prices of both generics and branded products.

Nearly 96% of respondents say that this is an issue affecting their respective pharmacy.

Collaboration aims to cut medication costs for patients with conditions ranging from high blood pressure to diabetes.

How drugmakers can navigate the program’s pricing challenges and regulatory developments.

Conditions require a disciplined approach to drug pricing.

Delays could harm older Americans, interest group states.

In what could presage a radical reshuffling of drug pricing and distribution, the insurer is dropping CVS Caremark as its PBM.

Illinois Governor JB Pritzker signed into a law a bill prohibiting PBM retaliation against pharmacists who disclose information during government proceedings.

Analysis requested by PhRMA indicates that these facilities charge anywhere from two to seven times what they originally paid.

Pharma Commerce team attends DIA's Annual Meeting for the first time.